Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson Sells 6,528 Shares

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 6,528 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the transaction, the executive vice president now owns 26,449 shares in the company, valued at $2,776,351.53. This trade represents a 19.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

John Bradley Sorenson also recently made the following trade(s):

• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38.

Boston Scientific Stock Performance

NYSE:BSX opened at $105.80 on Thursday. The company has a market capitalization of $155.93 billion, a PE ratio of 84.64, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $64.54 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a 50 day simple moving average of $95.50 and a two-hundred day simple moving average of $87.72.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Research analysts anticipate that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently modified their holdings of the business. Pitcairn Co. boosted its stake in Boston Scientific by 3.3% during the fourth quarter. Pitcairn Co. now owns 21,330 shares of the medical equipment provider’s stock worth $1,905,000 after acquiring an additional 682 shares in the last quarter. Arete Wealth Advisors LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $308,000. World Investment Advisors boosted its position in shares of Boston Scientific by 13.1% during the 4th quarter. World Investment Advisors now owns 13,215 shares of the medical equipment provider’s stock worth $1,180,000 after purchasing an additional 1,531 shares in the last quarter. Nicolet Advisory Services LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at about $223,000. Finally, Huntington National Bank increased its position in Boston Scientific by 5.2% in the 4th quarter. Huntington National Bank now owns 1,260,697 shares of the medical equipment provider’s stock valued at $112,605,000 after buying an additional 62,141 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Friday, January 10th. Wells Fargo & Company lifted their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Morgan Stanley increased their target price on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Citigroup boosted their price target on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, TD Cowen increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.